Clinical trial Recruiting at 1 site Interventional Ages 40 to 90

Managing homocysteine levels in Parkinson's patients on levodopa

Official title: Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

Run by Oregon Health and Science University · NCT06772220 · Data updated 2026-11-12

This study is testing if giving B vitamins to people with Parkinson's who are taking levodopa can lower their homocysteine levels and improve their thinking skills.

More s Disease trials

Quick facts

Study typeInterventional
Ages40 Years to 90 Years
SexAll
Enrollment150 (estimated)
SponsorOregon Health and Science University
Academic / other
Locations1 site (Portland, Oregon)
StatusRecruiting
StartedMarch 5, 2024
Main results expectedDecember 31, 2025
Study endsDecember 31, 2025
Registry record updatedJanuary 13, 2025
Trial IDNCT06772220 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 40-90 with a diagnosis of probable Parkinson's disease who are currently treated with a minimum of 300 mg/day of levodopa.

Probably not a fit

Patients with uncontrolled hypertension or those requiring insulin may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research investigates the levels of homocysteine in patients with Parkinson's disease who are being treated with levodopa. The study aims to determine if B vitamin therapy can effectively lower elevated homocysteine levels and assess the subsequent effects on cognitive function. Participants will receive folic acid, vitamin B6, and vitamin B12 as part of the intervention. The study focuses on understanding the relationship between homocysteine levels and cognitive health in this patient population.

Why it matters

Potential benefit: If successful, this approach could improve cognitive function and overall health in Parkinson's patients receiving levodopa.

How similar studies have gone: While there is limited data on this specific approach, studies addressing homocysteine management in neurological conditions have shown promising results.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria.
2. Currently treated with levodopa at a minimum dose of 300 mg/day
3. Montreal Cognitive Assessment (MOCA) ≥15
4. Demonstrated capacity to provide informed consent.
5. 40-90 years of age
6. Estimated glomerular filtration rate ≥60
7. Absence of uncontrolled hypertension in medical history
8. Absence of insulin use

Exclusion Criteria:

\-

Where it's running

  • Oregon Health & Science University (OHSU)
    Portland, Oregon, United States
    Recruiting

Study contacts

  • Principal investigator: Joseph Quinn, MD — Oregon Health & Science University (OHSU)
  • Study coordinator: Madeline Armendariz Sullivan
  • Email: PDResearch@ohsu.edu
  • Phone: 503-501-8478

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.